347 related articles for article (PubMed ID: 32671616)
1. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update.
Barnhill MS; Steinberg JM; Jennings JJ; Lewis JH
Curr Gastroenterol Rep; 2020 Jul; 22(9):47. PubMed ID: 32671616
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity of Inflammatory Bowel Disease Medications.
Shamberg L; Vaziri H
J Clin Gastroenterol; 2018 Sep; 52(8):674-684. PubMed ID: 30036242
[TBL] [Abstract][Full Text] [Related]
3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory bowel disease: current therapeutic options.
Domènech E
Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
[TBL] [Abstract][Full Text] [Related]
5. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease.
Núñez F P; Quera R; Bay C; Castro F; Mezzano G
J Crohns Colitis; 2022 Aug; 16(7):1168-1176. PubMed ID: 35044449
[TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.
Rojas-Feria M; Castro M; Suárez E; Ampuero J; Romero-Gómez M
World J Gastroenterol; 2013 Nov; 19(42):7327-40. PubMed ID: 24259964
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal and liver adverse effects of drugs used for treating IBD.
Rogler G
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):157-65. PubMed ID: 20227029
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of inflammatory bowel disease for the 21st century.
Robinson M
Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
[TBL] [Abstract][Full Text] [Related]
9. Current medical therapy for chronic inflammatory bowel diseases.
Tamboli CP
Surg Clin North Am; 2007 Jun; 87(3):697-725. PubMed ID: 17560421
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
11. Table: safety of drugs for IBD in pregnancy.
Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
[No Abstract] [Full Text] [Related]
12. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
Taylor KM; Ward MG; Blaker PA; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):473-486. PubMed ID: 28276819
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapeutic options in inflammatory bowel disease: an update.
Kho YH; Pool MO; Jansman FG; Harting JW
Pharm World Sci; 2001 Feb; 23(1):17-21. PubMed ID: 11344586
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
Sattler L; Hanauer SB; Malter L
Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
[TBL] [Abstract][Full Text] [Related]
15. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
16. Conventional drug therapy for inflammatory bowel disease.
Bryant RV; Brain O; Travis SP
Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
[TBL] [Abstract][Full Text] [Related]
17. Optimizing therapy for inflammatory bowel disease.
Robinson M
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
[TBL] [Abstract][Full Text] [Related]
18. Drugs for inflammatory bowel disease.
Med Lett Drugs Ther; 2018 Jul; 60(1550):107-114. PubMed ID: 30036352
[No Abstract] [Full Text] [Related]
19. Current pharmacotherapy for inflammatory bowel disease.
McKaig BC; Stack WA
Expert Opin Pharmacother; 1999 Nov; 1(1):3-14. PubMed ID: 11249561
[TBL] [Abstract][Full Text] [Related]
20. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice.
Seinen ML; van Asseldonk DP; Mulder CJ; de Boer NK
J Gastrointestin Liver Dis; 2010 Sep; 19(3):291-4. PubMed ID: 20922194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
